These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 19050293

  • 1. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis.
    Woodruff TM, Costantini KJ, Crane JW, Atkin JD, Monk PN, Taylor SM, Noakes PG.
    J Immunol; 2008 Dec 15; 181(12):8727-34. PubMed ID: 19050293
    [Abstract] [Full Text] [Related]

  • 2. Role of complement in motor neuron disease: animal models and therapeutic potential of complement inhibitors.
    Woodruff TM, Costantini KJ, Taylor SM, Noakes PG.
    Adv Exp Med Biol; 2008 Dec 15; 632():143-58. PubMed ID: 19025120
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis.
    Lee JD, Kumar V, Fung JN, Ruitenberg MJ, Noakes PG, Woodruff TM.
    Br J Pharmacol; 2017 Apr 15; 174(8):689-699. PubMed ID: 28128456
    [Abstract] [Full Text] [Related]

  • 4. Complement upregulation and activation on motor neurons and neuromuscular junction in the SOD1 G93A mouse model of familial amyotrophic lateral sclerosis.
    Heurich B, El Idrissi NB, Donev RM, Petri S, Claus P, Neal J, Morgan BP, Ramaglia V.
    J Neuroimmunol; 2011 Jun 15; 235(1-2):104-9. PubMed ID: 21501881
    [Abstract] [Full Text] [Related]

  • 5. Toll-Like Receptor-4 Inhibitor TAK-242 Attenuates Motor Dysfunction and Spinal Cord Pathology in an Amyotrophic Lateral Sclerosis Mouse Model.
    Fellner A, Barhum Y, Angel A, Perets N, Steiner I, Offen D, Lev N.
    Int J Mol Sci; 2017 Aug 01; 18(8):. PubMed ID: 28763002
    [Abstract] [Full Text] [Related]

  • 6. The complement factor C5a receptor is upregulated in NFL-/- mouse motor neurons.
    Humayun S, Gohar M, Volkening K, Moisse K, Leystra-Lantz C, Mepham J, McLean J, Strong MJ.
    J Neuroimmunol; 2009 May 29; 210(1-2):52-62. PubMed ID: 19286267
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Complement C5a-C5aR1 signalling drives skeletal muscle macrophage recruitment in the hSOD1G93A mouse model of amyotrophic lateral sclerosis.
    Wang HA, Lee JD, Lee KM, Woodruff TM, Noakes PG.
    Skelet Muscle; 2017 Jun 01; 7(1):10. PubMed ID: 28571586
    [Abstract] [Full Text] [Related]

  • 9. Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis.
    Lee JD, Kamaruzaman NA, Fung JN, Taylor SM, Turner BJ, Atkin JD, Woodruff TM, Noakes PG.
    J Neuroinflammation; 2013 Sep 26; 10():119. PubMed ID: 24067070
    [Abstract] [Full Text] [Related]

  • 10. Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
    Milanese M, Giribaldi F, Melone M, Bonifacino T, Musante I, Carminati E, Rossi PI, Vergani L, Voci A, Conti F, Puliti A, Bonanno G.
    Neurobiol Dis; 2014 Apr 26; 64():48-59. PubMed ID: 24361555
    [Abstract] [Full Text] [Related]

  • 11. Macrophage-mediated inflammation and glial response in the skeletal muscle of a rat model of familial amyotrophic lateral sclerosis (ALS).
    Van Dyke JM, Smit-Oistad IM, Macrander C, Krakora D, Meyer MG, Suzuki M.
    Exp Neurol; 2016 Mar 26; 277():275-282. PubMed ID: 26775178
    [Abstract] [Full Text] [Related]

  • 12. The anti-inflammatory peptide stearyl-norleucine-VIP delays disease onset and extends survival in a rat model of inherited amyotrophic lateral sclerosis.
    Goursaud S, Schäfer S, Dumont AO, Vergouts M, Gallo A, Desmet N, Deumens R, Hermans E.
    Exp Neurol; 2015 Jan 26; 263():91-101. PubMed ID: 25311268
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Acute intermittent hypoxia induced phrenic long-term facilitation despite increased SOD1 expression in a rat model of ALS.
    Nichols NL, Satriotomo I, Harrigan DJ, Mitchell GS.
    Exp Neurol; 2015 Nov 26; 273():138-50. PubMed ID: 26287750
    [Abstract] [Full Text] [Related]

  • 16. Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood.
    Mantovani S, Gordon R, Macmaw JK, Pfluger CM, Henderson RD, Noakes PG, McCombe PA, Woodruff TM.
    J Neuroimmunol; 2014 Nov 15; 276(1-2):213-8. PubMed ID: 25262158
    [Abstract] [Full Text] [Related]

  • 17. Autophagy activation and neuroprotection by progesterone in the G93A-SOD1 transgenic mouse model of amyotrophic lateral sclerosis.
    Kim J, Kim TY, Cho KS, Kim HN, Koh JY.
    Neurobiol Dis; 2013 Nov 15; 59():80-5. PubMed ID: 23891729
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Amyloid precursor protein (APP) contributes to pathology in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
    Bryson JB, Hobbs C, Parsons MJ, Bosch KD, Pandraud A, Walsh FS, Doherty P, Greensmith L.
    Hum Mol Genet; 2012 Sep 01; 21(17):3871-82. PubMed ID: 22678056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.